📊 NERV Key Takeaways
Is NERV a Good Investment? Thesis Analysis
Minerva Neurosciences is a pre-revenue pharmaceutical company with critically deteriorating financial health: negative stockholders' equity of -$140.7M indicates technical insolvency, with liabilities exceeding assets. The company is burning cash at -$13.5M annually with zero revenue generation, creating acute solvency risk absent successful drug commercialization.
Why Buy NERV? Key Strengths
- Substantial cash reserves of $82.3M providing near-term liquidity runway
- Relatively low long-term debt of $4.8M limiting refinancing burden
- Minimal insider selling activity suggesting some retained confidence
NERV Investment Risks to Consider
- Negative stockholders' equity of -$140.7M indicates balance sheet insolvency and distress
- Zero revenue with no pathway to profitability demonstrated in current period
- Continuous negative operating cash flow of -$13.5M depleting cash reserves without clinical/commercial validation
- Extreme accumulated losses of -$293.4M reflecting years of development costs without successful product launches
- Clinical/regulatory execution risk: success entirely dependent on unproven drug candidates reaching market
Key Metrics to Watch
- Cash runway depletion rate and burn acceleration
- Revenue realization from pipeline drug approvals or commercialization milestones
- Stockholders' equity restoration through dilutive financing or profitability
- Operating cash flow trajectory and operating expense discipline
- Debt covenant compliance and liquidity crisis indicators
NERV Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 36.28x current ratio provides a solid financial cushion.
NERV Profitability Ratios
NERV vs Healthcare Sector
How Minerva Neurosciences, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is NERV Overvalued or Undervalued?
Based on fundamental analysis, Minerva Neurosciences, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
NERV Balance Sheet & Liquidity
NERV 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Minerva Neurosciences, Inc.'s revenue has declined by 100% over the 5-year period, indicating business contraction. The most recent EPS of $0.19 reflects profitable operations.
NERV Growth Metrics (YoY)
NERV Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2021 | N/A | -$8.1M | $-0.19 |
| Q2 2021 | N/A | -$8.8M | $-0.25 |
| Q1 2021 | N/A | -$8.8M | N/A |
| Q3 2020 | N/A | -$8.1M | $-0.19 |
| Q2 2020 | N/A | -$12.2M | $-0.32 |
| Q1 2020 | N/A | -$12.2M | N/A |
| Q3 2019 | N/A | -$12.0M | N/A |
| Q2 2019 | N/A | -$12.4M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
NERV Capital Allocation
NERV SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Minerva Neurosciences, Inc. (CIK: 0001598646)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NERV
What is the AI rating for NERV?
Minerva Neurosciences, Inc. (NERV) has an AI rating of STRONG SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are NERV's key strengths?
Claude: Substantial cash reserves of $82.3M providing near-term liquidity runway. Relatively low long-term debt of $4.8M limiting refinancing burden.
What are the risks of investing in NERV?
Claude: Negative stockholders' equity of -$140.7M indicates balance sheet insolvency and distress. Zero revenue with no pathway to profitability demonstrated in current period.
What is NERV's revenue and growth?
Minerva Neurosciences, Inc. reported revenue of $0.0.
Does NERV pay dividends?
Minerva Neurosciences, Inc. does not currently pay dividends.
Where can I find NERV SEC filings?
Official SEC filings for Minerva Neurosciences, Inc. (CIK: 0001598646) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NERV's EPS?
Minerva Neurosciences, Inc. has a diluted EPS of $-34.67.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is NERV a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Minerva Neurosciences, Inc. has a STRONG SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is NERV stock overvalued or undervalued?
Valuation metrics for NERV: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy NERV stock in 2026?
Our dual AI analysis gives Minerva Neurosciences, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NERV's free cash flow?
Minerva Neurosciences, Inc.'s operating cash flow is $-13.5M, with capital expenditures of $16.3K.
How does NERV compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio 36.28 (avg: 2).